MedTrace Logo

T-Cell PET Imaging With [18F]F-AraG in Lung Cancer

NCT03311672 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2019-10-21

No results posted yet for this study

Summary

This is a single-center cross-sectional imaging study in patients with localized lung cancer undergoing immunotherapy with or without stereotactic radiation therapy as part of the companion clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer). Each patient will undergo a single \[18F\]F-AraG PET exam as part of this study. \[18F\]F-AraG will be administered at a single time point intravenously prior to PET imaging. Whole-body PET will be acquired along with a whole body low dose CT (PET/CT) used for attenuation correction and anatomic localization of \[18F\]F-AraG uptake, SUV calculation, and volumetric selection for radiomic analyses.

Conditions

Interventions

DRUG

[18F]F-Ara-G

Administered after two cycles of immunotherapy +/- stereotactic radiation therapy as part of the PET/CT scan.

DRUG

Pembrolizumab

All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.

RADIATION

PET/CT scan

Scan will be done after two cycles of immunotherapy +/- stereotactic radiation therapy.

Sponsors & Collaborators

Principal Investigators

  • Sue Yom, MD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-26
Primary Completion
2019-10-15
Completion
2019-10-15
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03311672 on ClinicalTrials.gov